Board Changes

RNS Number : 6017Q

Genflow Biosciences PLC

29 June 2022

 

PRESS RELEASE

29 June 2022

Genflow Biosciences Plc

("Genflow" or "the Company")

Board Changes

Genflow (LSE: GENF) is pleased to announce that Tamara Joseph and Dr Guy-Charles Fanneau de la Horie will join the Board as Independent Non-Executive Directors with immediate effect.

Ms Tamara Joseph

Tamara, a US resident, has extensive experience in both early-stage and commercial biotech companies in the US. Her expertise, within the biotech sector, includes public and private financings, M&A, global expansions and a Nasdaq uplisting. She has also supported Nasdaq financings in excess of $800m.

Her experience, spanning over 20 years, includes acting as a member of the executive team (as Chief Legal Officer and General Counsel) at multiple US publicly listed companies. Tamara is currently serving as Chief Legal Officer at Nasdaq listed, pharmaceutical firm, Spero Therapeutics Inc., a multi-asset, clinical-stage biopharmaceutical company. She previously served as Chief Legal Officer at Nasdaq listed, Millendo Therapeutics Inc., to support its transition to a publicly traded company, and as General Counsel at Enzyvant Therapeutics Inc., a rare disease company focused on regenerative medicine which is now a subdivision of Sumitomo Pharma.

Previously, Tamara has served as an adviser to the boards of five US publicly traded biotechs, including Cubist Pharmaceuticals Inc. (that was acquired by global healthcare leader, Merck & Co).

She currently holds two board and advisory roles with Heluna Health PHFE ("Heluna"), a Los Angeles based, leading fiscal sponsor for US public health programmes; and Boston based therapeutic non-profit organisation, BINA Farm. Within Heluna, Tamara is a member of its Executive Committee and Governance Committee.

Tamara's appointment reflects Genflow's aim of strengthening its presence in the US, where the longevity sector has gained enormous attention and attracted significant investment capital in excess of $3bn last year following investments made by high profile, ultra-high-net-worth individuals.

Dr Guy-Charles Fanneau de la Horie

Over the past 20 years, Guy-Charles has built, and led, biotech executive teams where he has acted as Chief Executive Officer.

During his tenures, he has successfully led IPOs and completed multiple fundraisings. Guy-Charles' expertise in the biotech field in both public and private companies encompasses launching and selling new drugs in untapped markets, with successful early access programs.

Specifically, Guy-Charles has served as Chief Executive Officer at three biotech companies, including, until very recently, Euronext Growth traded, Pherecydes Pharma, a biotech company that develops treatments against resistant bacterial infections; and Neovacs, a therapeutic vaccine company.

Guy-Charles has also held senior positions at Biogen, a Nasdaq listed global biotechnology company.

Guy-Charles managed the IPO and associated successful financing of Neovacs in 2010, and in 2021, led Pherecydes Pharma through an oversubscribed placing.

Genflow Growth

Both of these new appointments will greatly support the Company's growth and deeply strengthen and enhance the capital markets experience at board level. Importantly, and specifically, for the Company, the appointments will furnish the Board with broad and relevant experience of US listed biotech companies.

Following the appointment of Tamara and Guy-Charles, the total number of Directors on Genflow's Board will consist of four Independent Non-Executive Directors (including the Chairman), and one Executive Director.

Resignations

The Company also announces that Dr Gabrielle Silver, Independent Non-Executive Director, is stepping down from the Board owing to her time commitments and to focus on her other board roles.  In addition,  Professor Andrew Scott, is also stepping down as a Non-Executive Director in order to devote more time to his research and writing, aimed at raising awareness around longevity more broadly amongst the public and policymakers. The Board would like to take this opportunity to thank Gabrielle and Andrew for their valuable contribution to the Company over the course of Genflow's listing journey and landmark IPO.

Dr Eric Leire, Founder and CEO of Genflow, said: "We are delighted and indeed, honoured, to announce that Tamara Joseph and Dr Guy-Charles Fanneau de la Horie are joining the Genflow board. Tamara's outstanding track record in biotechnology, with particular exposure to listed firms in the US, dovetails with Genflow's growing exposure in the US following our recent distinguished collaborations with institutions such as the University of Rochester's Aging Research Center (RoAR). In addition, Guy-Charles' expertise in the biotechnology field and in capital markets specifically, will be an invaluable asset for Genflow as the Company continues to grow and perform against its stated strategy. 

Finally, on behalf of the board, I would also like to thank Gabrielle and Andrew for their commitment and for the support they have provided to Genflow on its journey to become the first longevity biotechnology firm to list in Europe."

For further information please contact:

Genflow Biosciences Plc
Dr Eric Leire Chief Executive	via Tancredi [phone]
Clear Capital Markets Ltd
Corporate Broker  Jonathan Critchley Keith Swann	[phone] [phone]
Tancredi Intelligent Communication Media Relations
Salamander Davoudi Helen Humphrey Benedetta Negri da Oleggio	[phone] [phone] [phone] [e-mail]

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.

To learn more visit www.genflowbio.com

-Ends-

 

END

 

 

BOABKCBPPBKKQAB